← back to search

Andrew Clear

Queen Mary University of London · GB
Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, and Cancer Immunotherapy and Biomarkers.
h-index
35
citations
6,336
works
134
NIH funding
primary concept
email

Recent publications

Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
Blood Advances 2022cited by 34position: middledoi
KDM5 inhibition offers a novel therapeutic strategy for the treatment of <i>KMT2D</i> mutant lymphomas
Blood 2021cited by 50position: middledoi
Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells
Cell 2020cited by 109position: middledoi
Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin
Haematologica 2018cited by 39position: middledoi
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Cell 2017cited by 1,123position: middledoi
Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium
Haematologica 2017cited by 48position: middledoi
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma
Nature Genetics 2015cited by 207position: middledoi
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia
Blood 2015cited by 185position: middledoi
Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations
Blood 2014cited by 70position: middledoi
Immune Checkpoint Blockade with Anti-PD-L1 Prevents Immune Dysfuntion and CLL Development in the TCL1 Adoptive Transfer Mouse Model
Blood 2014cited by 0position: middledoi
The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in Eµ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling
Blood 2014cited by 0position: middledoi
Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma
Gastroenterology 2013cited by 561position: middledoi
EZH2 mutations are frequent and represent an early event in follicular lymphoma
Blood 2013cited by 321position: middledoi
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups
Histopathology 2013cited by 34position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

John G. Gribben · University of Pennsylvania6 papers (2013–2018)Martina Seiffert · Rigshospitalet4 papers (2014–2018)Peter Lichter · German Cancer Research Center4 papers (2014–2018)Fabienne McClanahan · The Ohio State University Wexner Medical Center4 papers (2014–2015)Bola S. Hanna · Harvard University4 papers (2014–2018)Alan G. Ramsay · King's College London2 papers (2013–2014)Claudia Dürr · German Cancer Research Center2 papers (2014–2018)Thorsten Zenz · Monash University2 papers (2014–2018)John C. Riches · Queen Mary University of London2 papers (2013–2014)Stephan Stilgenbauer · Spital STS2 papers (2014–2018) · 2 papers (2014–2015)Jun Wang · Jiangsu Agri-animal Husbandry Vocational College1 papers (2013–2013)Angela Schulz · German Cancer Research Center1 papers (2018–2018)Rewas Fatah · Queen Mary University of London1 papers (2013–2013) · 1 papers (2013–2013)Donna Neuberg · Massachusetts General Hospital1 papers (2014–2014)Laura Z. Rassenti · National Foundation for Cancer Research1 papers (2014–2014)John F. Marshall · Queen Mary University of London1 papers (2013–2013)Fabienne Lucas · University of Washington1 papers (2018–2018)Hemant M. Kocher · Queen Mary University of London1 papers (2013–2013)